FI3604324T3 - Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa - Google Patents
Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa Download PDFInfo
- Publication number
- FI3604324T3 FI3604324T3 FIEP19181531.5T FI19181531T FI3604324T3 FI 3604324 T3 FI3604324 T3 FI 3604324T3 FI 19181531 T FI19181531 T FI 19181531T FI 3604324 T3 FI3604324 T3 FI 3604324T3
- Authority
- FI
- Finland
- Prior art keywords
- monoclonal antibody
- antibody
- impurity
- antibodies
- value
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 16
- 102000004169 proteins and genes Human genes 0.000 title claims 4
- 108090000623 proteins and genes Proteins 0.000 title claims 4
- 239000003014 ion exchange membrane Substances 0.000 title claims 2
- 239000000356 contaminant Substances 0.000 title 1
- 238000006073 displacement reaction Methods 0.000 title 1
- 238000011140 membrane chromatography Methods 0.000 title 1
- 239000012535 impurity Substances 0.000 claims 9
- 239000012528 membrane Substances 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000006143 cell culture medium Substances 0.000 claims 4
- 239000000306 component Substances 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 239000003011 anion exchange membrane Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 238000005341 cation exchange Methods 0.000 claims 1
- 239000012534 cell culture medium component Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229940072360 garamycin Drugs 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229910010272 inorganic material Inorganic materials 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/073179 WO2010019148A1 (en) | 2008-08-14 | 2008-08-14 | Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography |
| EP19181531.5A EP3604324B1 (en) | 2008-08-14 | 2008-08-14 | Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3604324T3 true FI3604324T3 (fi) | 2024-05-16 |
Family
ID=39899038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19181531.5T FI3604324T3 (fi) | 2008-08-14 | 2008-08-14 | Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10927144B2 (enExample) |
| EP (3) | EP2321337B2 (enExample) |
| JP (1) | JP5666447B2 (enExample) |
| KR (3) | KR101843915B1 (enExample) |
| CN (1) | CN102149724B (enExample) |
| AU (1) | AU2008360625C1 (enExample) |
| BR (1) | BRPI0823046B1 (enExample) |
| CA (1) | CA2731943C (enExample) |
| CY (1) | CY1122221T1 (enExample) |
| DK (2) | DK3604324T3 (enExample) |
| ES (3) | ES2527943T5 (enExample) |
| FI (1) | FI3604324T3 (enExample) |
| HR (2) | HRP20240472T1 (enExample) |
| HU (2) | HUE047316T2 (enExample) |
| IL (2) | IL210912B (enExample) |
| LT (2) | LT2848625T (enExample) |
| MX (1) | MX2011001506A (enExample) |
| PL (2) | PL2848625T3 (enExample) |
| PT (2) | PT2848625T (enExample) |
| RS (1) | RS59232B1 (enExample) |
| SI (2) | SI3604324T1 (enExample) |
| WO (1) | WO2010019148A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500413A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| KR101843915B1 (ko) | 2008-08-14 | 2018-04-02 | 제넨테크, 인크. | 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법 |
| KR20110091678A (ko) * | 2008-10-20 | 2011-08-12 | 아보트 러보러터리즈 | 단백질 ａ 친화성 크로마토그래피를 이용한 항체의 분리 및 정제 |
| NZ592097A (en) * | 2008-10-20 | 2013-01-25 | Abbott Lab | Viral inactivation during purification of il-12 and il-18 antibodies |
| MY161534A (en) † | 2010-05-25 | 2017-04-28 | Genentech Inc | Methods of purifying polypeptides |
| WO2012030512A1 (en) * | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
| WO2012077080A1 (en) * | 2010-12-10 | 2012-06-14 | Tracy Thompson | Compositions for separation methods |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| IL267585B (en) * | 2011-12-22 | 2022-09-01 | Genentech Inc | Ion exchange membrane chromatography |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201505203XA (en) * | 2013-02-26 | 2015-08-28 | Agency Science Tech & Res | Protein purification in the presence of nonionic organic polymers and electropositive surfaces |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| JP6163541B2 (ja) * | 2013-04-16 | 2017-07-12 | 旭化成メディカル株式会社 | 抗体タンパク質の精製方法 |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP2986307A4 (en) | 2014-01-03 | 2017-04-12 | Bio-rad Laboratories, Inc. | Removal of impurities from protein a eluates |
| CA3035853A1 (en) * | 2016-09-07 | 2018-03-15 | Glaxosmithkline Intellectual Property Development Limited | Methods for purifying antibodies |
| EP3509729A1 (en) | 2016-09-09 | 2019-07-17 | 3M Innovative Properties Company | Functionalized copolymers and use thereof |
| US10053368B1 (en) * | 2017-09-07 | 2018-08-21 | Chevron U.S.A. Inc. | Synthesis of AFX framework type molecular sieves |
| EP3546475A1 (en) * | 2018-03-27 | 2019-10-02 | Sanofi | Full flow-through process for purifying recombinant proteins |
| TWI814812B (zh) * | 2018-05-02 | 2023-09-11 | 美商里珍納龍藥品有限公司 | 用於評估生化過濾器的適合性的方法 |
| EP3810650A1 (en) * | 2018-06-19 | 2021-04-28 | Bristol-Myers Squibb Company | Methods of purifying proteins using chromatography |
| CN109324143B (zh) * | 2018-10-19 | 2021-10-29 | 张骐 | 利用二维液相分离制备抗体类产品相关杂质的方法 |
| CN109806916B (zh) * | 2019-03-15 | 2021-12-21 | 中科森辉微球技术（苏州）有限公司 | 高性能阴离子交换介质及其制备方法 |
| GB201911685D0 (en) * | 2019-08-15 | 2019-10-02 | Fujifilm Diosynth Biotechnologies Uk Ltd | Process for purifying monoclonal antibodies |
| KR20220112014A (ko) | 2021-02-03 | 2022-08-10 | 고인석 | 십전대보탕을 이용하여 만든 오리목뼈 간식 |
| CA3236213A1 (en) * | 2021-10-27 | 2023-05-04 | Eugene ZURLO | Compositions and methods for isolating proteins |
| CN118290514B (zh) * | 2024-06-05 | 2025-04-04 | 东曜药业有限公司 | 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| US4347322A (en) † | 1981-01-12 | 1982-08-31 | Nabisco Brands, Inc. | Chromatographic process for enzyme purification |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ES2193136T3 (es) | 1991-08-14 | 2003-11-01 | Genentech Inc | Variantes de inmunoglubina para receptores especificos de fc epsilon. |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| EP0656789B1 (en) | 1992-08-21 | 1997-12-17 | Genentech, Inc. | Method for treating a lfa-1-mediated disorder |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2106612C (en) * | 1993-09-21 | 2001-02-06 | Diana Pliura | Displacement chromatography process |
| US5714338A (en) | 1993-12-10 | 1998-02-03 | Genentech, Inc. | Methods for diagnosis of allergy |
| EP0739214B1 (en) | 1994-01-18 | 1998-03-18 | Genentech, Inc. | A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS |
| EP0749488A1 (en) | 1994-03-03 | 1996-12-27 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| EP1297847A3 (en) | 1996-01-23 | 2003-05-07 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| US6592905B1 (en) | 1996-01-31 | 2003-07-15 | Massey University | Production of an immunoglobulin enriched fraction from whey protein solutions |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| KR100532178B1 (ko) | 1996-11-27 | 2005-12-01 | 제넨테크, 인크. | 인간화 항-ＣＤ11ａ 항체 |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| ES2293682T5 (es) | 1997-05-15 | 2011-11-17 | Genentech, Inc. | Anticuerpo anti-apo2. |
| ATE321066T1 (de) | 1998-05-06 | 2006-04-15 | Genentech Inc | Anti-her2 antikörperzusammensetzung |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| DK1226177T3 (da) | 1999-10-29 | 2008-10-06 | Genentech Inc | Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf |
| US6479636B1 (en) † | 2000-04-11 | 2002-11-12 | Honiron Corporation (A Louisiana Corporation) | Sugarcane fractioning system |
| US6633462B2 (en) | 2000-07-13 | 2003-10-14 | Koninklijke Philips Electronics N.V. | Magnetoresistive angle sensor having several sensing elements |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| GB2372464B (en) † | 2001-02-22 | 2003-05-14 | Vivascience Ltd | Method of isolating a charged compound |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| WO2003033658A2 (en) | 2001-10-17 | 2003-04-24 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CN100522999C (zh) | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| JP4319979B2 (ja) † | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
| SI1561756T1 (sl) * | 2002-09-11 | 2016-02-29 | Chugai Seiyaku Kabushiki Kaisha | Postopek čiščenja proteinov |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| NZ543960A (en) | 2003-05-09 | 2008-11-28 | Univ Duke | CD20-specific antibodies and methods of employing same |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| JP4818917B2 (ja) | 2003-08-08 | 2011-11-16 | イミューノメディクス、インコーポレイテッド | 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体 |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| AU2004286938B2 (en) † | 2003-10-27 | 2011-06-30 | Wyeth | Removal of high molecular weight aggregates using hydroxyapatite chromatography |
| CA2597265C (en) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| KR101482791B1 (ko) † | 2005-03-11 | 2015-01-21 | 와이어쓰 엘엘씨 | 약한 분배성 크로마토그래피법 |
| WO2007108955A1 (en) † | 2006-03-20 | 2007-09-27 | Medarex, Inc. | Protein purification |
| JP2010505874A (ja) * | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| WO2009135656A1 (en) | 2008-05-06 | 2009-11-12 | Lonza Biologics Plc. | A method for the purification of antibodies using displacement chromatography |
| KR101843915B1 (ko) | 2008-08-14 | 2018-04-02 | 제넨테크, 인크. | 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법 |
| JP5731726B1 (ja) | 2014-06-26 | 2015-06-10 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2008
- 2008-08-14 KR KR1020117005824A patent/KR101843915B1/ko active Active
- 2008-08-14 PL PL14189582T patent/PL2848625T3/pl unknown
- 2008-08-14 KR KR1020187036563A patent/KR102196883B1/ko active Active
- 2008-08-14 ES ES08797895T patent/ES2527943T5/es active Active
- 2008-08-14 EP EP08797895.3A patent/EP2321337B2/en active Active
- 2008-08-14 HU HUE14189582A patent/HUE047316T2/hu unknown
- 2008-08-14 ES ES14189582T patent/ES2749190T3/es active Active
- 2008-08-14 RS RSP20191119 patent/RS59232B1/sr unknown
- 2008-08-14 BR BRPI0823046-3A patent/BRPI0823046B1/pt active IP Right Grant
- 2008-08-14 EP EP14189582.1A patent/EP2848625B1/en active Active
- 2008-08-14 MX MX2011001506A patent/MX2011001506A/es active IP Right Grant
- 2008-08-14 ES ES19181531T patent/ES2978373T3/es active Active
- 2008-08-14 JP JP2011522953A patent/JP5666447B2/ja active Active
- 2008-08-14 KR KR1020187008461A patent/KR20180033311A/ko not_active Ceased
- 2008-08-14 HR HRP20240472TT patent/HRP20240472T1/hr unknown
- 2008-08-14 SI SI200832219T patent/SI3604324T1/sl unknown
- 2008-08-14 AU AU2008360625A patent/AU2008360625C1/en active Active
- 2008-08-14 PT PT141895821T patent/PT2848625T/pt unknown
- 2008-08-14 DK DK19181531.5T patent/DK3604324T3/da active
- 2008-08-14 SI SI200832092T patent/SI2848625T1/sl unknown
- 2008-08-14 US US13/058,796 patent/US10927144B2/en active Active
- 2008-08-14 FI FIEP19181531.5T patent/FI3604324T3/fi active
- 2008-08-14 EP EP19181531.5A patent/EP3604324B1/en active Active
- 2008-08-14 LT LTEP14189582.1T patent/LT2848625T/lt unknown
- 2008-08-14 LT LTEP19181531.5T patent/LT3604324T/lt unknown
- 2008-08-14 PL PL19181531.5T patent/PL3604324T3/pl unknown
- 2008-08-14 PT PT191815315T patent/PT3604324T/pt unknown
- 2008-08-14 WO PCT/US2008/073179 patent/WO2010019148A1/en not_active Ceased
- 2008-08-14 DK DK14189582.1T patent/DK2848625T3/da active
- 2008-08-14 CA CA2731943A patent/CA2731943C/en active Active
- 2008-08-14 CN CN200880131059.7A patent/CN102149724B/zh active Active
- 2008-08-14 HU HUE19181531A patent/HUE066562T2/hu unknown
-
2011
- 2011-01-27 IL IL210912A patent/IL210912B/en active IP Right Grant
-
2018
- 2018-10-28 IL IL262657A patent/IL262657B/en active IP Right Grant
-
2019
- 2019-10-11 CY CY20191101072T patent/CY1122221T1/el unknown
- 2019-10-14 HR HRP20191848TT patent/HRP20191848T1/hr unknown
-
2021
- 2021-01-20 US US17/153,826 patent/US20210284685A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3604324T3 (fi) | Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa | |
| JP2011530592A5 (enExample) | ||
| TWI596107B (zh) | 單株抗體之新穎純化方法 | |
| ES2834967T3 (es) | Purificación de proteínas | |
| AU2011214361B2 (en) | Single unit antibody purification | |
| RU2014130017A (ru) | Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии | |
| JP2012507557A5 (enExample) | ||
| JP2008543868A5 (enExample) | ||
| US10112971B2 (en) | Protein purification in the presence of nonionic organic polymers and electropositive surfaces | |
| JP2012018171A5 (enExample) | ||
| US20160009762A1 (en) | Chromatographic purification of antibodies from chromatin-deficient cell culture harvests | |
| TW201309722A (zh) | 野生型或突變型白喉毒素之純化方法 | |
| FI3257564T4 (fi) | Ylikuormitus ja eluointikromatografia | |
| RU2011137030A (ru) | Способы очистки малых модулярных иммунофармацевтических белков | |
| JP2016509069A (ja) | 非イオン性有機ポリマー存在下、高導電率でのタンパク質精製 | |
| GB2443505B (en) | Nucleic acid purification method | |
| US20150225445A1 (en) | Mixed-mode antibody affinity separation matrix and purification method using the same, and the target molecules | |
| US20210040146A1 (en) | Protein purification process | |
| JP2007039454A5 (enExample) | ||
| US20210095261A1 (en) | Protein purification method and kit | |
| MX2024004764A (es) | Procedimiento para purificar una proteína de fusión que tiene un dominio fc de igg. | |
| CN109666065B (zh) | 一种快速制备高纯度达托霉素的方法 | |
| JP2010070490A (ja) | 抗体の精製方法 | |
| AU2022333819B2 (en) | Method for producing cytidine-5’-diphosphate compound | |
| EP1351960A1 (en) | Improved preparation of (4r, 5s, 6s)-3-[[(2r,3r)-2-[[[(s)-2-amino-3-methyl-1-oxobutyl]methyl]tetrahydro-3-furanyl]thio]-6-[(r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |